A5026096762- Influenza Virus Research Studies
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- interferon and immune responses
- RNA and protein synthesis mechanisms
- Tuberculosis Research and Epidemiology
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Viral Infections and Immunology Research
- Bacillus and Francisella bacterial research
- RNA Interference and Gene Delivery
- Cancer Research and Treatments
- Virus-based gene therapy research
- Immune responses and vaccinations
- bioluminescence and chemiluminescence research
- Lung Cancer Research Studies
- Tracheal and airway disorders
- Animal Virus Infections Studies
- Bacteriophages and microbial interactions
- SARS-CoV-2 and COVID-19 Research
Research Institute of Influenza
2017-2025
Ministry of Health of the Russian Federation
2021-2025
Peter the Great St. Petersburg Polytechnic University
2017-2021
Introduction. Respiratory syncytial virus (RSV) is the most common pathogen causing lower respiratory tract infections in children. RSV also poses a serious threat to elderly and immunocompromised patients. Developing therapy based on recombinant human antibodies block fusion (F) glycoprotein urgent reduce incidence of prevent associated complications. Aim. To design plasmid vectors for efficient production monoclonal antibody FM1 eukaryotic expression system targeting evaluate its activity...
MxA is a cytoplasmic protein induced in human cells exposed to type I and III interferons. It can inhibit various viruses, including influenza A, by blocking the early steps of viral replication cycle. The rapid advancement mRNA-based technology has allowed us evaluate antiviral activity MxA-mRNA, encoding intracellular protein, explore its potential as therapeutic agent. In this study, we used vitro transfection methods obtain functional, mature MxA-mRNA within cells. We also observed an...
New strategies providing protection against tuberculosis (TB) are still pending. The airborne nature of Mycobacterium (M.tb) infection assumes that the mucosal delivery TB vaccine could be a more promising strategy than systemic route immunization. We developed candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing truncated NS1 protein NS1(1–124) and full-length TB10.4 HspX proteins M.tb within an open reading frame. Flu/THSP was safe stimulated TB-specific CD4+...
Intranasal vaccination using influenza vectors is a promising approach to developing vaccines against respiratory pathogens due the activation of mucosa-associated immune response. However, there no clear evidence vector design that could be considered preferable. To find optimal structure an with modified NS genomic segment, we constructed four expressing identical transgene sequences inherited from F protein syncytial virus (RSV). Two were designed aiming at accumulation in cytosol....
BCG is the only licensed vaccine against Mycobacterium tuberculosis (M.tb) infection. Due to its intramuscular administration route, unable induce a local protective immune response in respiratory system. Moreover, has diminished ability long-lived memory T-cells which are indispensable for antituberculosis protection. Recently we described efficacy of new mucosal TB candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing TB10.4 and HspX proteins M.tb within an...
Recombinant viral vectors represent one of the most promising platforms for creating a new generation vaccines against tuberculosis. We constructed vaccine candidate based on cold-adapted influenza vector with truncated NS1 protein containing an insert tuberculosis ESAT-6 and Ag85A antigens. The recombinant virus possessed temperature-sensitive phenotype was attenuated mice when administered intranasally. Immunofluorescent staining Western blot showed expression in MDCK cells infected by...
Background/Objectives: Intranasal vaccination enhances protection against respiratory viruses by providing stimuli to the immune system at primary site of infection, promoting a balanced and effective response. Influenza vectors with truncated NS1 are promising vaccine approach that ensures pronounced local CD8+ T-cellular Here, we describe protective immunomodulating properties an influenza vector FluVec-N carrying C-terminal fragment SARS-CoV-2 nucleoprotein within open reading frame....
ВВЕДЕНИЕ: Онколитические вирусы представляют собой перспективный инструмент для лечения злокачественных опухолей головного мозга в составе комплексной терапии. ЦЕЛЬ ИССЛЕДОВАНИЯ: Разработка репортерных рекомбинантных вирусов гриппа А, экспрессирующих люциферазу NanoLuc, и оценка их безопасности при интракраниальном введении у крыс. МЕТОДЫ: Репортерные штаммы вируса обладающие хемилюминесцентной активностью, были получены методом обратной генетики. Генетический сегмент NS штаммов Т_NS124-Luc...
INTRODUCTION: Oncolytic viruses are a promising approach for treating malignant brain tumors as part of combination therapy. OBJECTIVE: To develop reporter influenza A expressing NanoLuc luciferase and evaluate their safety following intracranial administration in rats. METHODS: Chemiluminescent virus strains were obtained by reverse genetics. The NS genetic segment the T_NS124-Luc E_NS124-Luc encoded fusion protein that combined NS1 124 NanoLuc. In T_NS124-2A-Luc E_NS124-2A-Luc strains,...
We constructed a reporter influenza A/Puerto Rico/8/1934 virus expressing truncated 124aa N-terminal NS1 protein fused to luciferase sequence (NanoLuc) without signal peptide. The reproduction activity of the vector correlated well with luminescent in lysates infected cell cultures or mouse respiratory organ suspensions. Surprisingly, we found that enzymatic was present not only intracellular compartments but also culture supernatants as sera bronchiolar lavages mice. This fact allowed us...
The nucleoprotein (NP) of influenza virus is a multifunctional RNA binding protein. role NP in the adaptation viruses to host has been experimentally proved. Ambiguous data are available on attenuation A viruses, which characterized by ability replicate at low temperature (26°C) and inability high (39°C). Influenza donor strain A/Hong Kong/1/68/162/35 (H3N2), adapted growth temperature, differs from wild type 14 amino acid mutations internal non-structural proteins. Two occurred NP:...
Influenza viruses cause an acute respiratory infection, especially in the autumn-winter period. They are characterized by a high mutation frequency and annual seasonal epidemics. The detection of virus-neutralizing antibodies is important criterion assessment population immunity influenza vaccine effectiveness. In this study, method for determining titer blood serum has been developed. A new test, called luciferase neutralization assay, uses measurement bioluminescent signal as method....
Background: Influenza virus vectors are a promising approach to developing vaccines against respiratory pathogens due the advantage of activating mucosa-associated immune response. However, optimal way construct influenza vector syncytial (RSV) infection is not yet defined.Methods: To improve protective efficacy and immunogenicity NS vectors, we constructed compared four encoding identical antigenic regions RSV F protein but differing in design. The first group (NS-F NS-2AF) was designed...